Kineta Inc., of Seattle, presented preclinical in vitro and animal data at the Novel Antiviral Therapies for Influenza and Other Respiratory Viruses: Bench to Beside Conference in Austin, Texas, from a class of molecules discovered by Kineta and broadly inhibit influenza A and B, respiratory syncytial virus and coronavirus, which include Middle East respiratory syndrome.